title: Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
authors.forename: Lara
authors.initials: L
authors.lastname: Vallés
authors.forename: Marta
authors.initials: M
authors.lastname: González
authors.forename: Isabel
authors.initials: I
authors.lastname: Polo
authors.forename: Ana B
authors.initials: AB
authors.lastname: Enguita
authors.forename: Francisco
authors.initials: F
authors.lastname: Vanaclocha
authors.forename: Pablo L
authors.initials: PL
authors.lastname: Ortiz-Romero
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy*; D013848:Thigh; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins